Apellis reports $709M preliminary FY2024 U.S. net product revenue, COO Townsend to depart

Apellis Pharmaceuticals, Inc.

Preliminary FY2024 U.S. net product revenues $709M; SYFOVRE $611M (120% YoY growth), EMPAVELI $98M.
Cash and equivalents $410M as of Dec 31, 2024, up from $351M a year earlier.
sNDA for C3G/IC-MPGN expected early 2025; 2H 2025 launch if approved. Phase 3 FSGS and DGF studies planned 2H 2025.
COO Adam Townsend to depart Feb 21, 2025; David Acheson named EVP of commercial.
Keli Walbert elected to Board; ex-U.S. workforce reduced by ~40 employees.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Adam Townsend

Chief Operating Officer

APLS · Apellis Pharmaceuticals, Inc.

Effective: 2025-02-21
Filed: January 13, 2025, 6:59 PM ET

On January 10, 2025, the Company and Adam Townsend mutually agreed that Mr. Townsend will resign as the Company’s Chief Operating Officer effective as of February 21, 2025 (the “Separation Date”).

Appointed

Keli Walbert

Director

APLS · Apellis Pharmaceuticals, Inc.

Effective: 2025-01-08
Filed: January 13, 2025, 6:59 PM ET

On January 8, 2025, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Keli Walbert to the Board as a Class II director to serve until the Annual Meeting of Stockholders to be held in 2025 or until her successor has been duly elected and qualified or until her earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Townsend departed as Chief Operating Officer at Apellis Pharmaceuticals, Inc..

Action: resign
Role: Chief Operating Officer

Exact text from the filing

On January 10, 2025, the Company and Adam Townsend mutually agreed that Mr. Townsend will resign as the Company’s Chief Operating Officer effective as of February 21, 2025 (the “Separation Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Keli Walbert was elected as Director at Apellis Pharmaceuticals, Inc..

Action: elected
Role: Director

Exact text from the filing

On January 8, 2025, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Keli Walbert to the Board as a Class II director to serve until the Annual Meeting of Stockholders to be held in 2025 or until her successor has been duly elected and qualified or until her earlier death, resignation or removal.

View on SEC.gov

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-005052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.